Xenon Pharmaceuticals Inc. (XENE)
$39.1
Rating:
Recommendation:
Neutral
| Symbol | XENE |
|---|---|
| Price | $39.1 |
| Beta | 1.410 |
| Volume Avg. | 0.38M |
| Market Cap | 2.485B |
| Shares () | - |
| 52 Week Range | 26.25-43.57 |
| 1y Target Est | - |
| DCF Unlevered | XENE DCF -> | |
|---|---|---|
| DCF Levered | XENE LDCF -> | |
| ROE | -17.48% | Sell |
| ROA | -11.68% | Sell |
| Operating Margin | - | |
| Debt / Equity | 4.53% | Neutral |
| P/E | -16.57 | Strong Sell |
| P/B | 0 | Neutral |
Latest XENE news
About
Download (Excel)Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.